Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S: Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a preliminary analysis that showed statistically significant reductions (p<0.0001) in total psychiatric hospitalization rates in patients diagnosed with schizophrenia who were converted to once-monthly ABILIFY MAINTENA™ (aripiprazole) – an extended-release injectable suspension formulation of aripiprazole – compared to previous treatment with daily standard-of-care (SOC) oral antipsychotics.1 Relapse, or an acute exacerbation of the disease, can result in hospitalization.2 It also has been reported that hospitalization may contribute to higher health care costs.3 These data were presented in a poster at the 166th American Psychiatric Association (APA) Annual Meeting in San Francisco on May 21.1

Help employers find you! Check out all the jobs and post your resume.

Back to news